Global Health Q2 FY27 Results: Consolidated Net Profit ₹219 Crore on Total Income of ₹1,493 Crore
- Earnings
- healthcare services
Reviewed byKeshav SehgalBlacklitt Research
Global Health reported consolidated total income of ₹1,492.66 crore and net profit of ₹219.14 crore for the quarter ended 30 Sep 2026. Standalone total income was ₹1,233.98 crore and net profit ₹181.26 crore, the company said in a filing on 03 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹1,492.66 crore, up 33.4% YoY and 12.6% QoQ
- Net profit and EPS: ₹219.14 crore, up 38.3% YoY; basic EPS ₹8.21 against ₹5.89 a year earlier
- Finance costs: ₹28.09 crore, up 64.1% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹1,233.98 crore, up 30.0% YoY and 11.9% QoQ
- Net profit and EPS: ₹181.26 crore, up 29.3% YoY; basic EPS ₹6.75 against ₹5.22 a year earlier
- Profit before tax: ₹243.08 crore, up 31.4% YoY
- Finance costs: ₹17.07 crore, up 92.1% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,492.66 | 1,118.95 | +33.4% | 1,326.22 | +12.6% | |
| Revenue from operations | 1,469.04 | 1,099.28 | +33.6% | 1,304.05 | +12.7% |
| Other income | 23.62 | 19.67 | +20.1% | 22.16 | +6.5% |
| 219.14 | 158.40 | +38.3% | 157.25 | +39.4% | |
| Finance costs | 28.09 | 17.11 | +64.1% | 26.68 | +5.3% |
| Depreciation | 70.80 | 49.73 | +42.4% | 68.98 | +2.6% |
| Net profit margin | 14.68% | 14.16% | +0.53 pp | 11.86% | +2.82 pp |
| EPS, basic (₹) | 8.21 | 5.89 | +39.4% | 5.91 | +38.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income: up 38.3% against 33.4% for total income, and up 39.4% QoQ against 12.6%. Revenue from operations rose 33.6% YoY, faster than other income at 20.1%, and other income is only 1.6% of total income this quarter.
Finance costs rose 64.1% YoY to ₹28.09 crore, equal to 1.9% of total income, and depreciation rose 42.4% to ₹70.80 crore. The year-ago quarter carried a stamp duty reversal of ₹15.98 crore, shown as an exceptional item, so that quarter is part of the comparison base.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,233.98 | 949.23 | +30.0% | 1,102.78 | +11.9% | |
| Revenue from operations | 1,208.09 | 926.43 | +30.4% | 1,078.72 | +12.0% |
| Other income | 25.89 | 22.80 | +13.5% | 24.06 | +7.6% |
| 181.26 | 140.20 | +29.3% | 137.31 | +32.0% | |
| Profit before tax | 243.08 | 185.05 | +31.4% | 183.11 | +32.7% |
| Finance costs | 17.07 | 8.88 | +92.1% | 15.89 | +7.4% |
| Depreciation | 56.15 | 37.43 | +50.0% | 54.60 | +2.8% |
| Tax expense | 61.82 | 44.85 | +37.8% | 45.80 | +35.0% |
| Net profit margin | 14.69% | 14.77% | -0.08 pp | 12.45% | +2.24 pp |
| EPS, basic (₹) | 6.75 | 5.22 | +29.3% | 5.11 | +32.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 29.3% YoY, slower than total income (30.0%) and profit before tax (31.4%). Tax expense rose 37.8% to ₹61.82 crore, which is 25.4% of profit before tax of ₹243.08 crore.
Finance costs rose 92.1% YoY to ₹17.07 crore, or 1.4% of total income, while other income of ₹25.89 crore equals 10.7% of profit before tax. Consolidated net profit of ₹219.14 crore is ₹37.88 crore higher than the standalone figure of ₹181.26 crore.
The healthcare services business is reported as a single segment. The company signed a Business Transfer Agreement in April 2026 for a 79-bedded super speciality hospital in Indore. Existing capacity was 3,811 beds on 30 Sep 2026. The year ended 31 Mar 2026 carried labour code impacts of ₹35.20 crore standalone and ₹36.60 crore consolidated, shown as exceptional items.
Inference
The filing shows ₹9.92 crore of dividend paid and ₹14.23 crore spent on purchase of treasury shares in the six months to 30 Sep 2026. The Board approved a project budget of ₹997 crore, including land costing ₹165.82 crore, for a 500-bedded hospital at Ghaziabad. The company says the land will be funded from internal accruals and the whole project from internal accruals and debt. The statutory auditors issued unmodified limited review reports on both sets of results.
Not known from the filing: the split between internal accruals and debt for the ₹997 crore project, and the revenue the Ghaziabad hospital will earn beyond the 3-4 year phased capacity addition.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
